A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Clinical trial NCT04893551 · TERMINATED

Trial details

NCT number: NCT04893551
Sponsor: BerGenBio ASA
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Neoplasms

Start date: 2021-02-25
Primary completion: 2022-06-27
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.